Myriad Genetics Inc. faces heightened pressure as key diagnostic pipeline setbacks deepen concerns while stocks have been trading down by -45.72 percent
Click Here for a Millionaire's POV on Trading MYGN
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Market Insights For Active Traders
- FY26 revenue guidance was cut to $770M-$790M from $860M-$880M, signaling a meaningful reset in growth expectations and weaker end-market demand for Myriad Genetics Inc.
- The new outlook sits well below prior consensus near $863.6M, which is likely to keep pressure on MYGN until traders see evidence the bar is now achievable.
- Management kept adjusted gross margin guidance at 66%-67%, suggesting pricing and cost control are holding up even as volume and growth expectations weaken.
- TD Cowen lowered its MYGN price target to $4 from $6, citing soft Q2 performance, payer friction, and weaker prenatal trends, reinforcing a cautious stance from the Street.
Weekly Update Jul 27 – Jul 31, 2026: On Saturday, August 01, 2026 Myriad Genetics Inc. stock [NASDAQ: MYGN] is trending down by -45.72%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Myriad Genetics sits in a challenged but not terminal position within molecular diagnostics. Revenue of ~$825M with high 70% gross margin underscores a solid franchise, but EBIT margin of -47% and ROE around -77% highlight a structurally loss-making model. Cash of ~$115M and current ratio 2.4 provide near-term liquidity, yet recurring negative operating cash flow and FCF (-$8.3M and -$11.5M this quarter) plus leverage (debt/equity 0.63) constrain strategic flexibility.
Technically, MYGN is in a clear downtrend, with the stock breaking sharply from the mid‑$5s to sub‑$3 in days. The plunge from $5.71 to a $2.86–$2.93 range reflects capitulation selling on heavy volume, followed by only tentative stabilization. The dominant trend is bearish; rallies are short-covering, not accumulation. The first actionable level is resistance around $3.40–$3.50; below that, $2.80 is the key support for short-term traders watching for breakdown continuation.
More Breaking News
- VRT Stock Powers Higher On AI Data Center Boom
- HL Stock Trades Sideways As Financial Strength Supports Silver Play
- DNN Stock Drifts Lower As Uranium Traders Watch Key Support
- BTE Stock Grinds Higher As Street Targets Diverge
Fundamentally, guidance cuts (FY26 revenue now $770–$790M vs prior $860–$880M) and payer friction put MYGN clearly below healthcare and diagnostics peers on growth, profitability, and visibility. Sell-side target cuts (e.g., TD Cowen $6 to $4, Hold) reinforce a “show-me” phase. Relative to profitable diagnostics leaders, Myriad trades cheap on sales but appropriately penalized for losses and execution risk. Base case: trading range $2.50–$4.00 near term, with resistance at $4, skewed to the downside until cost structure and reimbursement trends improve.
Quick Financial Overview
Myriad Genetics Inc. is coming off a tough reset. The company cut its FY26 revenue view to a $770M-$790M range from $860M-$880M, clearly below the prior consensus near $863.6M. That tells traders demand is running lighter than previously expected, particularly given the weaker Q2 cited by management. At the same time, MYGN is holding its adjusted gross margin outlook at 66%-67%, which shows the problem is growth, not pricing power or unit economics.
On the chart, the damage is obvious. After trading around $5.45 earlier in the week, MYGN broke sharply, with a plunge to the $3.32-$3.40 area and then a further slide toward roughly $2.86-$2.91. That is a massive repricing in a few sessions, consistent with a guidance shock. Intraday, a 5-minute candle showing trade between about $3.10 and $3.26 before dipping to the high-$2.80s confirms aggressive selling into any bounce.
Under the hood, the financials show why the market is punishing the stock. Myriad Genetics Inc. generated about $190.7M in quarterly revenue with a solid 70% gross margin, yet it still posted an operating loss near $38.9M and net loss of about $43.2M. Profitability ratios are deeply negative, with return on equity and return on assets both well below zero. Cash remains decent at about $115.2M and liquidity ratios are healthy, but free cash flow of roughly -$11.5M and heavy accumulated losses highlight ongoing execution risk.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.